Information Provided By: 
Fly News Breaks for December 20, 2017
TXMD
Dec 20, 2017 | 07:49 EDT
Deutsche Bank analyst Esther Rajavelu says that as expected, TherapeuticsMD announced the FDA's acceptance of the resubmitted TX-004 new drug application with an action date of May 29, 2018, for the treatment of moderate to severe dyspareunia in menopausal women. The analyst continues to anticipate approval of both TX-004 and TX-001 in 2018. She believes the company in the company weeks will announce the TX-001 new drug application submission and a $150M of term loan financing. Rajavelu keeps a Buy rating on the shares with a $9 price target.
News For TXMD From the Last 2 Days
There are no results for your query TXMD
